Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
SRPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$34.10 - $173.25
Previous CloseN/A
Volume185.86K
Average Volume (3M)4.30M
Market Cap
$3.58B
Enterprise Value$3.81B
Total Cash (Recent Filing)$1.35B
Total Debt (Recent Filing)$1.34B
Price to Earnings (P/E)19.6
Beta1.05
Next Earnings
Jul 30, 2025EPS Estimate
0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.60
Shares Outstanding98,277,030
10 Day Avg. Volume7,903,635
30 Day Avg. Volume4,301,289
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.29
Price to Sales (P/S)0.00
P/FCF Ratio-10.40
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue0.59
Enterprise Value/Gross Profit2.42
Enterprise Value/Ebitda5.41
Forecast
1Y Price Target
$96.57Price Target Upside165.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceSarepta Therapeutics reported preliminary total product revenue that significantly exceeded both analyst and consensus estimates, indicating strong performance.
Market GrowthThe launch of Elevidys continues to be strong, with revenue significantly surpassing estimates and numerous patients being treated.
Regulatory ApprovalsThe Japanese approval of Elevidys represents the first approval for patients under four years of age.
Bears Say
Market CompetitionThere is significant competition modeled for PMOs, with uncertainty around FDA affecting the outlook.
Operational ChallengesSRPT reported several headwinds in 1Q including administrative delays and site capacity constraints, which raise questions about the cadence of the launch.
Regulatory ChallengesElevidys was approved despite the partial clinical hold in Europe due to a possibly drug-related patient death in the US.
---
Ownership Overview
4.10% Insiders
28.90% Mutual Funds
31.97% Other Institutional Investors
14.96% Public Companies and
Individual Investors
SRPT FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $34.10 and its highest was $173.25 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is $3.58B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Jul 30, 2025 which is in 73 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on May 06, 2025. The company reported -$4.6 earnings per share for the quarter, missing the consensus estimate of -$3.207 by -$1.393.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is 0.9.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 98,277,030 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of -$4.6 in its last earnings report, missing expectations of -$3.207. Following the earnings report the stock price went down -21.455%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Currently, no hedge funds are holding shares in SRPT
---
Sarepta Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$96.57 (165.08% Upside)
$96.57 (165.08% Upside)
Blogger Sentiment
Bullish
SRPT Sentiment 92%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 357.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $248.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 40.0%
Last 30 Days ▲ 40.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.55%
12-Months-Change
Fundamentals
Return on Equity
-23.61%
Trailing 12-Months
Asset Growth
7.47%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
---
SRPT Company Deck
---
SRPT Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant revenue growth and strong demand projections for the future. However, challenges such as the tragic patient safety incident, administrative delays, and site capacity imbalances have led to a downward revision of revenue guidance. Despite these challenges, the company remains optimistic about long-term demand and continues to work on addressing the issues.Read More>---
SRPT Stock 12 Month Forecast
Average Price Target
$96.57
▲(165.08% Upside)
Technical Analysis
Alkermes
―
Blueprint Medicines
―
Axsome Therapeutics
―
Revolution Medicines
―
Legend Biotech
―
---